Biologic Therapy for Inflammatory. Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida
|
|
- Cecil Freeman
- 6 years ago
- Views:
Transcription
1 Biologic Therapy for Inflammatory Bowel Disease: Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida Learning Objectives Evaluate evidence regarding the clinical i l value of early use of biologics in the treatment paradigm for Inflammatory Bowel Disease (IBD) Discuss some of the newer biologic therapies for IBD Review the safety profile of available biologic therapies for IBD 1
2 Etiologic Theories in Inflammatory Bowel Disease (IBD) Genetic Predisposition IBD Mucosal Immune System (immunoregulatory defect) Environmental Triggers (Lumenal bacteria, infection, NSAIDs) Pathogenesis of IBD Neurath MK. Nat Rev Immunol 14; 14:
3 Goals for Treatment of IBD Evolving expectations and therapeutic strategies The expanding role of biologics Rethinking our treatment approach Surgery Biologics MTX AZA/6MP Systemic Steroids Budesonide Antibiotics 5-ASA Improve patient quality of life Induce Clinical Remission Maintain Clinical Remission Decrease surgical rates Minimize disease-related complications Current Expectations for IBD Therapy Mucosal Healing Decrease hospitalizations Minimize therapy related complications 3
4 Sustained Deep Remission Goals Response Remission Deep Remission Clinical Parameters Improved symptoms No symptoms No symptoms Mucosal Healing S U S T A I N E D Mucosal Healing Associated with: Better quality of life Fewer hospitalizations Fewer surgeries Longer time to clinical relapse Reduction in risk of dysplasia/cancer Role of Tumor Necrosis Factor (TNF) in the Pathogenesis of IBD IL: interleukin RIPK: receptor-interacting protein kinase TIMP1: tissue inhibitor of matrix metalloproteinases 1 TRAF2: TNF receptor-associated factor 2 IECs: intestinal epithelial cells MMPs: matrix metalloproteinase MLCK: myosin light chain kinase NF-κB: nuclear factor-κb Neurath MK, Nat Rev Immunol 14;14:
5 Anti-TNF Biologics Golimumab: PURSUIT-SC Induction of Remission 7 p< rcentage of patients 3 Per 3.3 p< Placebo (n=251) Golimumab /1 mg (n=253) Golimumab / mg (n=257) Sandborn et al. Gastroenterol 14;146:
6 Golimumab: PURSUIT-M Maintenance of Remission 7 p<.1 6 p=.1 Percentage of patients Placebo (n=154) Golimumab 5 mg (n=151) Golimumab 1 mg (n=151) Sandborn et al. Gastroenterol 14; 146:96-19 Golimumab: PURSUIT-M Mucosal Healing 7 6 p=.11 p=.2 Pe ercentage of patients Placebo (n=154) Golimumab 5 mg (n=151) Golimumab 1 mg (n=151) Sandborn et al. Gastroenterol 14;146:
7 Early Use of Biologics: PRECISE Patients (%) Any <1 1 - <2 2 - <5 5 CD duration (yrs) Placebo Certolizumab Sandborn et al. NEJM 7;357:239 Early Use of Biologics: CHARM Patients (%) <2 yrs 2 - <5 yrs 5 yrs Disease duration Placebo Adalimumab EOW Adalimumab qw Schreiber et al. Gastroenterol 7;132:A147 7
8 SONIC TRIAL Study of Biologic and Immunomodulator Naïve Patients in Crohn s Disease Subjects 21 years of age or older with: Moderate-to-Severe Crohn s disease (CDAI* 2 and 45) No prior exposure to biologic i agents or immunomodulators Normal TPMT At least 1 of the following criteria: Corticosteroid-dependent Being considered for second (or more) course of steroids in past year 5-ASA failures: inadequate response to mesalamine 2.4 g/d or more (or equivalent) for at least 4 weeks Budesonide failures: inadequate response to budesonide 6 mg/d or more for at least 4 weeks *Crohn s Disease Activity Index Columbel JF et al. N Engl J Med 1; 362: Definitions Corticosteroid-free remission CDAI < 15 points and have not received any dose of oral systemic corticosteroids (prednisone or equivalent) for 3 weeks and have not received budesonide at a dose greater than 6 mg/day for 3 weeks Mucosal healing Complete absence of mucosal ulcerations in the colon and terminal ileum as assessed by video endoscopy Columbel JF et al. N Engl J Med 1; 362:
9 Main Extension Visitsit Week * Week 2 Week 6 Week 1 Week 14 Week 18 Week 22 Week 26* Week 3 Week 38 Week 42 Week 46 Week 5 Week 54 Infusions Azathioprine 2.5 mg/kg + placebo infusions Study Design Randomization of patients Infliximab 5 mg/kg + placebo capsules Infliximab 5 mg/kg + Azathioprine 2.5 mg/kg Primary Endpoint (Corticosteroid-free Remission at Week 26) Secondary Endpoint (Week 5) * Endoscopy performed at Weeks & 26 Corticosteroid-Free Clinical Remission at Week 26 Primary Endpoint ion of Patients (%) Proporti p=.9 p< p=.22 p= /17 75/169 96/169 AZA + placebo IFX + placebo IFX+ AZA Columbel JF et al. N Engl J Med 1; 362:
10 Mucosal Healing at Week 26 tion of Patients (%) Proport p<.1 p=.23 p= /19 28/93 47/17 AZA + placebo IFX + placebo IFX+ AZA Columbel JF et al. N Engl J Med 1; 362: Corticosteroid-Free Clinical Remission at Week 26 by Baseline CRP p<.1 p=.27 p= % p=.53 p= % p= % 35.2%.3% 27.6% 25/71 27/67 35/69 27/98 48/11 61/96 CRP <.8 CRP >.8 AZA + Placebo IFX + Placebo IFX + AZA Columbel JF et al. N Engl J Med 1; 362:
11 Corticosteroid-Free Clinical Remission at Week 26 by Baseline Endoscopy Status p<.1 p=.117 p= % 5.5% 3.4% p=.927 p=.372 p=.688.7%.% 33.3% 3% p=.3 p= % p= % 21.4% 35/115 5/99 68/111 11/27 12/36 12/3 6/28 13/34 16/28 Lesions (n=325) No Lesions (n=93) No Endoscopy or UTD (n=9) AZA + Placebo IFX + Placebo IFX + AZA Columbel JF et al. N Engl J Med 1; 362: Summary of Adverse Events Through Week 3 Pts with 1 AE, n (%) AZA IFX IFX Ttl Total + placebo + placebo + AZA (n=161) (n=163) (n=179) (n=53) 138 (85.7%) 139 (85.3%) 156 (87.2%) 433 (86.1%) Pts with 1 39 (24.2%) 2%) 26 (16.%) 25 (14.%) 9 (17.9%) SAE, n (%) Serious infections 8 (5.%) 4 (2.5%) 6 (3.4%) 18 (3.6%) Columbel JF et al. N Engl J Med 1; 362:
12 Conclusions of SONIC Infliximab/AZA combination > AZA alone Infliximab/AZA combination > infliximab monotherapy Infliximab monotherapy > AZA monotherapy Patients with high baseline CRP and/or ulcers at baseline colonoscopy had a particularly strong benefit from early infliximab Safety was similar in all 3 arms: there was no trend toward an increased risk of serious infections with infliximab Columbel JF et al. N Engl J Med 1; 362: UC SUCCESS Randomized, double blind trial Evaluating efficacy and safety of 16 weeks of treatment in moderate to severe UC* 231 patients, all TNF α naïve 3 arms: IFX/AZA IFX + placebo oral pills AZA + placebo IV infusions * Mayo score 6-12 Panaccione R et al. Gastroenterol 14; 146:392-12
13 UC SUCCESS Corticosteroid-free remission: - total Mayo score of 2 points or less - no individual sub-score exceeding 1 point - no corticosteroids on board at week 16 Mucosal healing - Mayo endoscopy sub-score of or 1 at week 16 Panaccione R et al. Gastroenterol 14; 146:392- UC SUCCESS: Corticosteroid-Free Remission at Week 16 6 p=.32 6 in steroid-free remisson at week p= p= Percentage of pts 1 AZA (N=76) IFX (N=77) IFX/AZA (N-78) Panaccione R et al. Gastroenterol 14; 146:392-13
14 UC SUCCESS: Mucosal Healing at Week ith mucosal healing at week p=.28 p= p= Percentage wi 3 1 AZA (N=76) IFX (N=77) IFX/AZA (N-78) Panaccione R et al. Gastroenterol 14; 146:392- Anti-TNF Safety Concerns Serious Infections Reactivation of TB, Hepatitis B Opportunistic (i.e.: Histoplasmosis) Malignancies Skin cancer NHL Hepatosplenic T cell lymphoma Hypersensitivity reactions Infusion/Injection site reaction Serum sickness/delayed hypersensitivity Exacerbation of CHF Psoriasis Demyelination Lupus-like syndrome Liver toxicity 14
15 TREAT Registry Crohn s Therapy Resource, Evaluation and Assessment Tool Prospective observational registry of patients with CD 6273 adult CD patients enrolled in TREAT -34 patients (17,712 pt-yrs) have received infliximab patients (13,251 pt-yrs) have not received infliximab Mean length of followup is 5.2 years Of patients who have received infliximab, 89.9% have received 2 infusions Lichtenstein, G. et al. Am J Gastroenterol 12; 17: Patient Characteristics Infliximab- Other treatments treated patients only ypatients p-value Number of patients Disease severity Moderate-Severe 3.6% 1.7% <.1 Severe-Fulminant 2.5%.6% <.1 Concomitant Medications Immunomodulators 52.% 32.1% <.11 Corticosteroids 47.8% 31.4% <.1 Hospitalization within 14.2% 8.8% <.1 previous year Surgery within 17.4% 13.6% <.1 previous year Lichtenstein, G et al. Am J Gastroenterol 12; 17:
16 TREAT Registry: Mortality Hazard Ratio 95% CI Use of infliximab Use of 6MP/AZA/MTX Use of prednisone * Use of narcotic * * analgesics Age * *p<.1 Lichtenstein, G et al. Am J Gastroenterol 12; 17: TREAT Registry: Serious Infections Hazard Ratio 95% CI Mod-Sev Disease * Use of infliximab * Use of 6MP/AZA/MTX Use of prednisone * Use of narcotic analgesics * *p<.1 *p=.6 *p=.2 Lichtenstein, G. et al. Am J Gastroenterol 12; 17:
17 TREAT Registry: Malignancy Hazard Ratio p Baseline Age 1.59 <.1* Use of infliximab Use of 6MP/AZA/MTX Disease Duration * Smoking * Lichtenstein, G. et al. Am J Gastroenterol 14; 19: Anti-integrin Biologics Natalizumab Binds to the α4 integrins, ubiquitous in inflammatory cells in circulation Can bind to VCAM throughout the body Associated with progressive multifocal leukoencephalopathy (PML) 17
18 Vedolizumab: Mechanism of Action Vedolizumab: Vedolizumab binding blocks α4β7 binding to MAdCAM-1 GEMINI-I: Vedolizumab in UC Randomized, double-blind, placebo- controlled Patient population: Moderate to severe UC (Mayo scores 6-12) Sigmoidoscopy sub-score of at least 2 Unsuccessful previous treatment (either lack of response or adverse side effect) with either steroids, immunomodulators or anti TNF agents Previous anti-tnf failure in at least % of patients Feagan B et al. NEJM 13; 369:
19 GEMINI-I: Vedolizumab in UC Induction Phase (6 weeks): 2 cohorts: 374 patients (placebo v vedolizumab 3 mg at Wks and patients got open label vedolizumab at Wks and 2 Maintenance phase (52 weeks): patients with response in either cohort at week 6 were randomized to one of 3 groups: Placebo vedolizumab every 4 weeks Vedolizumab every 8 weeks Feagan B et al. NEJM 13; 369: GEMINI-I: Vedolizumab in UC Induction Outcomes at Week p<.1 Percentage of pts p= p= Clinical Response Clinical Remission Mucosal Healing Placebo (n=149) Vedolizumab (n=225) Feagan B et al. NEJM 13; 369:
20 GEMINI-I: Vedolizumab in UC Maintenance Outcomes at Week 52 Pe ercentage of patients p<.1 p< p<.1 p< p<.1 p=.1 Clinical Remission (wk 52) Mucosal Healing (wk 52) Steroid-free Remission (wk 52) Placebo (n=126) Vedolizumab q 8wks (n=122) Vedolizumab q 4wks (n=125) Feagan B et al. NEJM 13; 369: GEMINI-II: Vedolizumab in CD Randomized, double-blind,,placebo- controlled Patient population: Moderate to severe CD (CDAI 2-45) Evidence of active inflammation (either high CRP, multiple ulcers on colonoscopy, or elevated fecal calprotectin, plus ulcers on radiographic imaging or capsule endoscopy Unsuccessful previous treatment (either lack of response or adverse side effect) with either steroids, immunomodulators or anti TNF agents Previous anti-tnf failure in at least 5% of patients Sandborn W et al. NEJM 13; 369:
21 GEMINI-II: Vedolizumab in CD Induction Phase (6 weeks): 2 cohorts: 368 patients (placebo v vedolizumab 3 mg at Wks and patients got open label vedolizumab at Wks and 2 Maintenance phase (52 weeks): patients with response in either cohort at week 6 were randomized to one of 3 groups: Placebo vedolizumab every 4 weeks Vedolizumab every 8 weeks Sandborn W et al. NEJM 13; 369: GEMINI-II: Vedolizumab in CD Induction Outcomes at Week p=.23 Perc centage of patients p= Clinical Remission CDAI-1 Response Placebo (n=148) Vedolizumab (n=2) Sandborn W et al. NEJM 13; 369:
22 GEMINI-II: Vedolizumab in CD Maintenance Outcomes at Week 52 7 Pe ercentage of patients p=.4 p< p=.5 p= p=.4 p= Clinical Remission CDAI-1 Response Steroid-free Remission Placebo (n=153) Vedolizumab q 8wks (n=154) Vedolizumab q 4wks (n=154) Sandborn W et al. NEJM 13; 369: Vedolizumab: Safety Rare infusion related reactions and hypersensitivity Not recommended in patients with active severe infection until the infection is controlled No cases of PML have been observed Most common adverse reactions: Nasopharyngitis* -Rash Headache -Bronchitis Arthralgia -Influenza Nausea -Back pain Upper resp tract infection -Pruritis Fatigue -Sinusitis Cough -Oropharyngeal pain 22
23 Conclusions The goal of treatment for IBD is a deep remission since there will be modification of the natural history of the disease. Earlier use of biologic therapy may be beneficial in a subset of patients with more aggressive disease. Combination therapy results in greater level of mucosal healing and greater rate of corticosteroid free remission than monotherapy with azathioprine or infliximab in patients with moderate to severe CD and UC. The anti-tnf therapies are relatively safe based on data from TREAT registry. Golimumab is efficacious in the induction and maintenance of remission in moderate-severe UC. Vedolizumab is an efficacious, safe agent that is FDA approved for moderate to severe UC and CD. 23
September 12, 2015 Millie D. Long MD, MPH, FACG
Update on Biologic Therapy in 2015 September 12, 2015 Millie D. Long MD, MPH, FACG Assistant Professor of Medicine Inflammatory Bowel Disease Center University of North Carolina-Chapel Hill Outline Crohn
More informationAn Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD
An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University
More informationUpdate on Biologics in Ulcerative Colitis. Scott Plevy, MD University of North Carolina Chapel Hill, NC
Update on Biologics in Ulcerative Colitis Scott Plevy, MD University of North Carolina Chapel Hill, NC Objectives Discuss the latest advances in the pharmacologic management of ulcerative colitis Describe
More informationIBD Updates. Themes in IBD IBD management journey. New tools for therapeutic monitoring. First-line treatment in IBD
IBD Updates Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida Themes in IBD 213 First-line treatment in IBD New tools for therapeutic monitoring Biologic therapy for CD and
More informationSevere IBD: What to Do When Anti- TNFs Don t Work?
Severe IBD: What to Do When Anti- TNFs Don t Work? David T. Rubin, MD, FACG Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Interim Chief, Section of Gastroenterology, Hepatology and
More informationIBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants
IBD Understanding Your Medications Thomas V. Aguirre, MD Santa Barbara GI Consultants IBD Understanding Your Medications (& Your Doctor) Thomas V. Aguirre, MD Santa Barbara GI Consultants Disclosure I
More informationDisclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists
What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists Disclosures No financial relationships to disclose. 1 Learning Objectives Case 24M with ileocolonic
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationCommon Questions in Crohn s Disease Therapy. Case
Common Questions in Crohn s Disease Therapy Jean-Paul Achkar, MD, FACG Kenneth Rainin Chair for IBD Research Cleveland Clinic Case 23 yo male with 1 year history of diarrhea, abdominal pain and 15 pound
More informationNew treatment options in IBD: today and the future. Silvio Danese Istituto Clinico Humanitas, Milan, Italy
New treatment options in IBD: today and the future Silvio Danese Istituto Clinico Humanitas, Milan, Italy Date of preparation: October 2014 GLO/EYV/2014-00010h Overview of the late-stage IBD drug pipeline*
More informationMono or Combination Therapy with. Individualized Approach
Mono Combination Therapy with Biologics i in IBD: Developing an Individualized Approach David T. Rubin, MD, FACG Co-Direct, Inflammaty Bowel Disease Center Fellowship Program Direct University of Chicago
More informationBeyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center
Beyond Anti TNFs: positioning of other biologics for Crohn s disease Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center Objectives: To define high and low risk patient and disease features
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Assistant Professor of Clinical Pediatrics Division of Gastroenterology,
More informationEmerging g therapies for IBD: A practical approach to positioning. Sequential Therapies for IBD
Emerging g therapies for IBD: A practical approach to positioning Stephen B. Hanauer, MD Sequential Therapies for IBD Disease Severity at Presentation Severe Anti-TNF +/IS Cyclosporine (UC) Colectomy (UC)
More informationBiologics in 2016: How Do We Select the Most Appropriate Agent? Gary R. Lichtenstein, MD, FACG University of PA School of Medicine Philadelphia, PA
Biologics in 2016: How Do We Select the Most Appropriate Agent? Gary R. Lichtenstein, MD, FACG University of PA School of Medicine Philadelphia, PA Overview Indications and Drug Selection Contraindications
More informationChoosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball
Choosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball Siddharth Singh, MD, MS Assistant Professor of Medicine Division of Gastroenterology Division of Biomedical
More informationBiologics in IBD. Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College
Biologics in IBD Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College Case 30 year old man diagnosed with ulcerative proctitis diagnosed in 2003 Had been maintained
More informationCCFA. Crohns Disease vs UC: What is the best treatment for me? November
CCFA Crohns Disease vs UC: What is the best treatment for me? November 8 2009 Ellen J. Scherl,, MD, FACP,AGAF Roberts Inflammatory Bowel Disease Center Weill Medical College Cornell University New York
More informationAzathioprine for Induction and Maintenance of Remission in Crohn s Disease
Azathioprine for Induction and Maintenance of Remission in Crohn s Disease William J. Sandborn, MD Chief, Division of Gastroenterology Director, UCSD IBD Center Objectives Azathioprine as induction and
More informationGionata Fiorino VEDOLIZUMAB E IBD. Un nuovo target terapeutico
Gionata Fiorino VEDOLIZUMAB E IBD Un nuovo target terapeutico Anti cell adhesion molecules Danese S, NEJM 2011 6 Steps leukocyte recruitment Fiorino G. et al. 2010 Vedolizumab Blocks Fewer Biological Pathways
More informationEmerging Therapies in IBD 2006
Overview Emerging Therapies in IBD 26 David T. Rubin, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center University of Chicago Describe the unmet needs of therapy in IBD Emerging biologic
More informationPosition of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy
Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy Stephen B. Hanauer, MD University of Chicago Potential Conflicts: Centocor/Schering, Abbott, UCB, Elan, Berlex, PDL Goals of Treatment
More informationLatest Meds Approved for IBD: What are they and how do they work?
Latest Meds Approved for IBD: What are they and how do they work? JAMES LORD, MD PHD BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON MEDICAL CENTER SEPT 30, 2018 Brief history of IBD Dr. Burrill Crohn JAMA
More informationRecent Advances in the Management of Refractory IBD
Recent Advances in the Management of Refractory IBD Raina Shivashankar, M.D. Assistant Professor of Medicine Division of Gastroenterology and Hepatology Thomas Jefferson University Philadelphia, PA Outline
More informationSelection and use of the non-anti- TNF biological therapies: Who? When? How?
Selection and use of the non-anti- TNF biological therapies: Who? When? How? Asher Kornbluth, MD Clinical Professor of Medicine The Henry D. Janowitz Division of Gastroenterology The Icahn School of Medicine
More informationBiologic Therapy for Ulcerative Colitis in 2015
5/6/215 Biologic Therapy for Ulcerative Colitis in 215 John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University Bressler B, Marshall JK, et al. Gastroenterology 215;148: 135-58
More informationMedical Therapy for Pediatric IBD: Efficacy and Safety
Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission
More informationInitiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease
Initiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease The Case for Starting with Anti-TNFα Agents Maria Oliva-Hemker, M.D. Chief, Division of Pediatric Gastroenterology &
More informationHow to Optimize Induction and Maintenance Responses: Definitions and Dosing Advances in Inflammatory Bowel Disease December 6, 2009
How to Optimize Induction and Maintenance Responses: Definitions and Dosing 2009 Advances in Inflammatory Bowel Disease December 6, 2009 Fernando Velayos MD MPH University of California, San Francisco
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Gary R. Lichtenstein, MD, FACG Professor of Medicine Director, Inflammatory Bowel Disease Program University of Pennsylvania Philadelphia, PA In my
More informationMucosal Healing in Crohn s Disease. Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium
Mucosal Healing in Crohn s Disease Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium Mucosal Lesions in CD: General Features CD can affect the entire GI tract
More informationTreatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10
Current Management of IBD: From Conventional Agents to Biologics Stephen B. Hanauer, M.D. University of Chicago Treatment Goals Induce and maintain response/ remission Prevent complications Improve quality
More informationPositioning New Therapies
Positioning New Therapies Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker Disclosure Stephen Hanauer, MD has disclosed
More informationRisk = probability x consequence
Explaining Risks of IBD Therapy to Parents and Patients December 4, 2009 CCFA Advances in IBD Hollywood, FL Corey A. Siegel Assistant Professor of Medicine, Dartmouth Medical School Director, Dartmouth-Hitchcock
More informationΑπό τη θεωρία στη πράξη: Συζήτηση κλινικών περιστατικών. Κωνσταντίνος Κατσάνος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστήμιο Ιωαννίνων
Από τη θεωρία στη πράξη: Συζήτηση κλινικών περιστατικών Κωνσταντίνος Κατσάνος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστήμιο Ιωαννίνων Conflict of interest By means of this, the speaker confirms that
More informationNew treatment options in UC. Rob Bryant IBD Consultant Royal Adelaide Hospital
New treatment options in UC Rob Bryant IBD Consultant Royal Adelaide Hospital Talk Outline 1. Raising expectations 2. Optimising UC therapy 3. Clinical trials 4. What s new on the PBS? 5. Questions 1.
More informationCOPYRIGHT. Inflammatory Bowel Disease What Every Clinician Needs to Know. Adam S. Cheifetz, MD. Director, Center for Inflammatory Bowel Disease
Inflammatory Bowel Disease What Every Clinician Needs to Know Adam S. Cheifetz, MD Director, Center for Inflammatory Bowel Disease Beth Israel Deaconess Medical Center Associate Professor of Medicine Harvard
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Brian Feagan, MD, FACG Professor of Medicine and Epidemiology and Biostatistics Director, Robarts Clinical Trials Robarts Research Institute University
More informationUlcerative Colitis Therapy. Faculty Disclosure. Acknowledgements 28/11/2013. Amy Morse November 30/13
Ulcerative Colitis Therapy Amy Morse November 30/13 GI for GP s Jasper AB Faculty Disclosure Faculty: Amy Morse Relationships with commercial interests: Grants/Research Support: Therapeutic Fellowship
More informationJoin the conversation at #GIFORUMCCFA
1 Join the conversation at #GIFORUMCCFA 2 Disclosures In accordance with the ACCME Standards for Commercial Support of CME, the speakers for this course have been asked to disclose to participants the
More informationCROHN'S DISEASE/ULCERATIVE COLITIS TREATMENT ALGORITHM
CROHN'S DISEASE/ULCERATIVE COLITIS TREATMENT ALGORITHM Crohn's Disease Ulcerative Colitis Steroids x 2 No prior AZA/6-MP Biologic Agent AZA/6-MP STEP-UP MANAGEMENT APPROACH Advantages Patients attain remission
More informationModerately to severely active ulcerative colitis
Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients
More informationIndications for use of Infliximab
Indications for use of Infliximab Moscow, June 10 th 2006 Prof. Dr. Dr. Gerhard Rogler Klinik und Poliklinik für Innere Medizin I Universität Regensburg Case report 1989: Diagnosis of Crohn s disease of
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 October 2012 REMICADE 100 mg, powder for concentrate for solution for infusion B/1 vial (CIP code: 562 070-1) Applicant:
More informationPersonalized Medicine in IBD
Personalized Medicine in IBD Anita Afzali MD, MPH Assistant Professor of Medicine Director, Inflammatory Bowel Diseases Program University of Washington Harborview Medical Center CCFA April 2 nd, 2016
More information1. Comparative effectiveness of vedolizumab
Cost-effectiveness of vedolizumab (Entyvio ) for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were
More informationPharmacotherapy of Inflammatory Bowel Disorder
PHARMACY / MEDICAL POLICY 5.01.563 Pharmacotherapy of Inflammatory Bowel Disorder Effective Date: Feb. 14, 2018 Last Revised: April 1, 2018 Replaces: Extracted from 5.01.550 RELATED MEDICAL POLICIES: 11.01.523
More informationTreatment of Inflammatory Bowel Disease. Michael Weiss MD, FACG
Treatment of Inflammatory Bowel Disease Michael Weiss MD, FACG What is IBD? IBD is an immune-mediated chronic intestinal disorder, characterized by chronic or relapsing inflammation within the GI tract.
More informationJohn F. Valentine, MD Inflammatory Bowel Disease Program University of Utah
John F. Valentine, MD Inflammatory Bowel Disease Program University of Utah Hawaii 1/20/2017 DISCLOSURES Research Support: NIH, Pfizer, Celgene, AbbVie, Roche/Genentech, Takeda, CCFA OBJECTIVES Review
More informationEndpoints for Stopping Treatment in UC
Endpoints for Stopping Treatment in UC Jana G. Hashash, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center Division of Gastroenterology, Hepatology, and Nutrition University of Pittsburgh
More informationAnne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014
Management and Medical Therapies for Crohn disease: strategies to enhance mucosal healing Anne Griffiths MD, FRCPC SickKids Hospital, University of Toronto Buenos Aires, August 16, 2014 New onset Crohn
More informationCommunicating with the IBD Patient: How to convey risks and benefits
Communicating with the IBD Patient: How to convey risks and benefits October 30, 2011 ACG Postgraduate Course National Harbor, Maryland Corey A. Siegel, MD Assistant Professor of Medicine Dartmouth Medical
More informationTherapy for Inflammatory Bowel Disease
Therapy for Inflammatory Bowel Disease Jonathan P. Terdiman, MD Professor of Clinical Medicine Clinical Director, Center for Colitis and Crohn s Disease University of California San Francisco, CA UC: Current
More informationOptimizing Therapies for Severe Ulcerative Colitis October 19, 2014
Optimizing Therapies for Severe Ulcerative Colitis October 19, 2014 Ellen J. Scherl, MD, FACP, FACG, AGAF, FASGE, NYSGEF Director Jill Roberts Center for Inflammatory Bowel Disease Jill Roberts IBD Research
More informationOf Treatment For Inflammatory Bowel Diseases
Balancing The Risks And Benefits Of Treatment For Inflammatory Bowel Diseases Corey A. Siegel, MD Assistant Professor of Medicine Dartmouth Medical School Director, Inflammatory Bowel Diseases Center Dartmouth-Hitchcock
More informationPersonalized Medicine in IBD: Where Are We in 2013
Personalized Medicine in IBD: Where Are We in 2013 David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University Medical Center What is Personalized
More informationUlcerative colitis (UC) is a chronic inflammatory
Induction and Maintenance Therapy with Vedolizumab, a Novel Biologic Therapy for Ulcerative Colitis Feagan BG, Rutgeerts P, Sands BE, et al; GEMINI 1 Study Group. Vedolizumab as induction and maintenance
More informationTo help protect your privacy, PowerPoint prevented this external picture from being automatically downloaded. To download and display this picture,
To help protect your privacy, PowerPoint prevented this external picture from being automatically downloaded. To download and display this picture, click Options in the Message Bar, and then click Enable
More informationPharmacotherapy of Inflammatory Bowel Disorder
PHARMACY / MEDICAL POLICY 5.01.563 Pharmacotherapy of Inflammatory Bowel Disorder Effective Date: June 9, 2019* Last Revised: Feb. 12, 2019 Replaces: Extracted from 5.01.550 RELATED MEDICAL POLICIES: 11.01.523
More informationOPTIMAL USE OF IMMUNOMODULATORS AND BIOLOGICS Edward V. Loftus, Jr., MD, FACG
1C: Advances in Inflammatory Bowel Disease OPTIMAL USE OF IMMUNOMODULATORS AND BIOLOGICS Edward V. Loftus, Jr., MD, FACG narrow interpretation of this presentation topic would A be a discussion of dosing
More informationAgenda. Predictive markers in IBD. Management of ulcerative colitis. Management of Crohn s disease
Agenda Predictive markers in IBD Management of ulcerative colitis Management of Crohn s disease 2 Patients With UC (%) Distribution of UC Disease Severity at Presentation 1 Fulminant disease (9%) 8 6 4
More informationLatest Treatment Updates for Crohn s Disease: Tailoring Therapy David G. Binion, M.D.
Latest Treatment Updates for Crohn s Disease: Tailoring Therapy David G. Binion, M.D. Co-Director, IBD Center Director, Nutrition Support Service UPMC Presbyterian Hospital Division of Gastroenterology,
More informationBiologics, Novel Therapeutic Approaches in Inflammatory Bowel Diseases
Biologics, Novel Therapeutic Approaches in Inflammatory Bowel Diseases Walter Reinisch Univ-Klinik für Innere Medizin III Abt. Gastroenterologie & Hepatologie AKH Wien The Biologic s evolution From availabilitydriven
More informationOutline. Biologic Drugs in Inflammatory Bowel Disease Dr. Jason Etzel MD The Vancouver Clinic. Biologic Drugs. Biologic Drugs. Biologic Drugs Anti-TNF
Outline Biologic Drugs in Inflammatory Bowel Disease Dr. Jason Etzel MD The Vancouver Clinic Types of biologic drugs How do they work? How effective are they? Safety/Toxicity concerns with biologics Biologic
More informationAdverse Events From Biologic Agents in IBD
Adverse Events From Biologic Agents in IBD David A. Schwartz, MD, FACG Director, Inflammatory Bowel Disease Center Professor of Medicine Vanderbilt University Medical Center Case Page 1 of 24 28 yo with
More information2nd Nottingham IBD Masterclass, 2017
2nd Nottingham IBD Masterclass, 217 Positioning IL12/IL23 blockade in the Crohn s disease treatment algorithm Prof James Lindsay, Consultant Gastroenterologist, Barts Health NHS Trust Professor in Inflammatory
More informationManagement of Moderate to Severe Ulcerative Colitis
Management of Moderate to Severe Ulcerative Colitis Neilanjan Nandi, MD Assistant Professor of Medicine Associate Program Director Division of Gastroenterology Drexel University College of Medicine Hahnemann
More informationNew and Future Adhesion Molecule Based Therapies in IBD
New and Future Adhesion Molecule Based Therapies in IBD Brian G. Feagan Professor of Medicine, Epidemiology and Biostatistics University of Western Ontario Robarts Clinical Trials London, Ontario, Canada
More informationPEDIATRIC INFLAMMATORY BOWEL DISEASE
PEDIATRIC INFLAMMATORY BOWEL DISEASE Alexis Rodriguez, MD Pediatric Gastroenterology Advocate Children s Hospital Disclosers Abbott Nutrition - Speaker Inflammatory Bowel Disease Chronic inflammatory disease
More informationThe Refractory Crohn s Disease
The Refractory Crohn s Disease Patient David T. Rubin, MD, FACG Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Interim Chief, Section of Gastroenterology, Hepatology and Nutrition
More informationImproving outcome of Inflammatory Bowel Disease in children
Improving outcome of Inflammatory Bowel Disease in children Dinesh Pashankar, MD Pediatric Gastroenterologist Director- Pediatric IBD program Yale University School of Medicine Pediatric Gastroenterology
More informationPractical Risk Management Tools for Patients with IBD. Garth Swanson MD Rush University Medical Center
Practical Risk Management Tools for Patients with IBD Garth Swanson MD Rush University Medical Center IBD Therapy Severity Tysabri Surgery Infliximab, i Adalimumab, Certilizumab Corticosteroids, Immunomodulators
More informationOptimal Use of Immunomodulators and Biologics
3/17/214 Optimal Use of Immunomodulators and Biologics Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic Rochester, Minnesota, U.S.A. Loftus Disclosures
More informationTitle: Author: Journal:
IMPORTANT COPYRIGHT NOTICE: This electronic article is provided to you by courtesy of Ferring Pharmaceuticals. The document is provided for personal usage only. Further reproduction and/or distribution
More informationSelby Inflamm Bowel Dis. 2008:14:
Medical Management of Inflammatory Bowel Disease Freddy Caldera D.O. Assistant Professor Division of Gastroenterology Objectives Discuss Crohn s disease and Ulcerative Colitis Discuss Medications for Inflammatory
More informationCrohn s
Crohn s Disease David T. Rubin, MD, AGAF Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology, and Nutrition Co-Director, Digestive Diseases Center @IBDMD Disclosures
More informationAli Keshavarzian MD Rush University Medical Center
Treatment: Step Up or Top Down? Ali Keshavarzian MD Rush University Medical Center Questions What medication should IBD be treated with? Can we predict which patients with IBD are high risk? Is starting
More informationMedical Management of Inflammatory Bowel Disease
Medical Management of Inflammatory Bowel Disease John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University John K. Marshall: Conflicts of Interest Speaker: AbbVie, Allergan, Ferring,
More informationPharmacotherapy of Inflammatory Bowel Disorder
PHARMACY / MEDICAL POLICY 5.01.563 Pharmacotherapy of Inflammatory Bowel Disorder Effective Date: May 1, 2018 Last Revised: April 18, 2018 Replaces: Extracted from 5.01.550 RELATED MEDICAL POLICIES: 11.01.523
More informationMucosal healing: does it really matter?
Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does it really matter? Professor Jean-Frédéric Colombel, New York, USA Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does
More informationThe Best of IBD at UEGW (Crohn s)
The Best of IBD at UEGW (Crohn s) Iyad Issa MD Head of Gastroenterology, Rafik Hariri Univ Hosp Adjunct Faculty, School of Medicine, Leb Univ Founding Faculty, School Of Medicine, Leb Am Univ 1 The Best
More informationTechnology appraisal guidance Published: 26 August 2015 nice.org.uk/guidance/ta352
Vedolizumab for treating moderately to severely erely active Crohn's disease after prior therapy Technology appraisal guidance Published: 26 August 2015 nice.org.uk/guidance/ta352 NICE 2017. All rights
More informationWHY HAVE WE NOT FINALLY FIGURED OUT COMBINATION THERAPY?
WHY HAVE WE NOT FINALLY FIGURED OUT COMBINATION THERAPY? Siew Ng, Professor MBBS, FRCP, (Lon, Edin), PhD (Lond), AGAF, FHKCP, FHKAM (medicine) Department of Medicine and Therapeutics Chinese University
More informationBest Practices in the Diagnosis and Treatment of Inflammatory Bowel Disease
Best Practices in the Diagnosis and Treatment of Inflammatory Bowel Disease Mark Lazarev, MD Summary Inflammatory bowel disease (IBD) is a complex disease that is costly both in terms of medical costs
More informationTherapies for IBD: the Pipeline. New Therapeutic Agents in IBD
Therapies for IBD: the Pipeline New Therapeutic Agents in IBD William J. Sandborn, MD Professor & Chief, Division of Gastroenterology Director, UCSD IBD Center Budesonide Oral MMX budesonide Rectal budesonide
More informationDefinitions. Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency)
CROHN S DISEASE Definitions Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency) Recurrence: The reappearance of lesions after surgical resection Endoscopic remission:
More informationCrohn s Disease: Should We Treat Based on Symptoms or Based on Objective Markers of Inflammation?
Crohn s Disease: Should We Treat Based on Symptoms or Based on Objective Markers of Inflammation? Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic
More informationPersonalized Medicine. Selecting the Right First-line Biologic Agent. Gene Expression Profiles Crohn s Disease. The Right Treatment
Personalized Medicine Selecting the Right First-line Biologic Agent William Tremaine, M.D. Maxine and Jack Zarrow Professor Mayo Clinic Rochester, MN, USA The Right Treatment Pretreatment Genomic Analysis
More informationVedolizumab: policing leukocyte traffic
Oxford Inflammatory Bowel Disease MasterClass Vedolizumab: policing leukocyte traffic Dr Brian Feagan, London, Canada Vedolizumab : Policing Lymphocyte Traficking Brian G. Feagan Professor of Medicine,
More informationDRAFT. Remission rates, calculated using observed case (OC) analyses were as follows: Year 1 Year 2 Year 3 Year 4 All patients 62.
DRAFT New Efficacy Data Shows Cimzia (certolizumab pegol) Provides Long-Term Remission of Moderate to Severe Crohn s Disease Regardless of Prior Anti-TNF Exposure, According to Data Presented at DDW Oral
More informationBalancing the Risk and Benefit of Immunomodulator and Biologic Therapy in Patients with IBD
Balancing the Risk and Benefit of Immunomodulator and Biologic Therapy in Patients with IBD Gary R. Lichtenstein, MD Professor of Medicine University of Pennsylvania School of Medicine Director, Center
More informationProgress in Inflammatory Bowel Disease
Progress in Inflammatory Bowel Disease Gary R Lichtenstein, MD Director, Center for IBD University of Pennsylvania School of Medicine Hospital of the University of PA Philadelphia, PA Disclosure Research,
More informationCLINICAL MEDICAL POLICY
Policy Name: Policy Number: Responsible Department(s): CLINICAL MEDICAL POLICY Tysabri (natalizumab) MP-042-MD-WV Provider Notice Date: 10/01/2017 Original Effective Date: 11/01/2017 Annual Approval Date:
More informationSynopsis. Adalimumab M Clinical Study Report R&D/16/1088. Individual Study Table Referring to Part of Dossier: Volume:
Synopsis AbbVie Inc. Name of Study Drug:, Azathioprine, Prednisone Name of Active Ingredient: Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Title
More informationImmunogenicity of Biologic Agents and How to Prevent Sensitization
Immunogenicity of Biologic Agents and How to Prevent Sensitization William J. Sandborn, MD Professor and Chief, Division of Gastroenterology Director, UCSD IBD Center La Jolla, California, USA Learning
More informationOptimizing the effectiveness of anti-tnf therapy in paediatric IBD
Optimizing the effectiveness of anti-tnf therapy in paediatric IBD Anne Griffiths MD, FRCPC Co-Lead, Inflammatory Bowel Disease Center Northbridge Chair in IBD Hospital for Sick Children, Professor of
More informationTumor necrosis factor-alpha antibody for maintenace of remission in Crohn s disease (Review)
Tumor necrosis factor-alpha antibody for maintenace of remission in Crohn s disease (Review) Behm BW, Bickston SJ This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration
More informationAnti tumor necrosis factor (TNF) agents have
Achieving Clinical Response and Remission in Moderate-to-Severe Ulcerative Colitis With Golimumab Sandborn WJ, Feagan BG, Marano C, et al; PURSUIT-SC Study Group. Subcutaneous golimumab induces clinical
More informationSYNOPSIS. Issue Date: 25 Oct 2011
SYNOPSIS Issue Date: 25 Oct 2011 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Janssen Research & Development STELARA Ustekinumab Protocol No.: Title of Study: Study Name:
More information